WO2015172341A8 - 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 - Google Patents
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 Download PDFInfo
- Publication number
- WO2015172341A8 WO2015172341A8 PCT/CN2014/077521 CN2014077521W WO2015172341A8 WO 2015172341 A8 WO2015172341 A8 WO 2015172341A8 CN 2014077521 W CN2014077521 W CN 2014077521W WO 2015172341 A8 WO2015172341 A8 WO 2015172341A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glypican
- cell antigen
- bispecific antibody
- antigen
- specific recognition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
公开了一种针对磷脂酰肌醇蛋白多糖-3和T细胞抗原的双特异性抗体及其制备方法和用途，所述抗体包含特异性识别磷脂酰肌醇蛋白多糖-3的第一功能域、特异性识别人T细胞抗原CD3的第二功能域和连接上述功能域的接头，可用于制备治疗或预防肿瘤的药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/077521 WO2015172341A1 (zh) | 2014-05-14 | 2014-05-14 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/077521 WO2015172341A1 (zh) | 2014-05-14 | 2014-05-14 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015172341A1 WO2015172341A1 (zh) | 2015-11-19 |
| WO2015172341A8 true WO2015172341A8 (zh) | 2016-04-28 |
Family
ID=54479162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2014/077521 WO2015172341A1 (zh) | 2014-05-14 | 2014-05-14 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015172341A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102529012B1 (ko) | 2016-04-22 | 2023-05-09 | 크라제 메디컬 씨오 리미티드 | 세포성 면역요법을 위한 조성물 및 방법 |
| US20200255505A1 (en) * | 2017-08-09 | 2020-08-13 | Eureka Therapeutics, Inc. | Cells Expressing Cell Surface Receptors and Antibodies |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| AU2022388928A1 (en) | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ507381A (en) * | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| MY145073A (en) * | 2004-07-09 | 2011-12-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
| CA2738545A1 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
-
2014
- 2014-05-14 WO PCT/CN2014/077521 patent/WO2015172341A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015172341A1 (zh) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| EP3621641A4 (en) | ANTI-CD3 BINDING DOMAINS AND ANTIBODIES CONTAINING THEM AND THE METHOD OF MANUFACTURING AND USING THEM | |
| WO2019086500A3 (en) | Bispecific 2+1 contorsbodies | |
| EP3538152A4 (en) | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF | |
| WO2017136820A3 (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| WO2017152085A8 (en) | Combination therapy with anti-cd73 antibodies | |
| EP3575322A4 (en) | ANTI-PD-1 MONOCLONAL ANTIBODY, PROCESS OF PREPARATION AND APPLICATION | |
| WO2013155526A3 (en) | Sortase- modified vhh domains and uses thereof | |
| WO2018031490A3 (en) | Anti-ox40 binding proteins | |
| WO2012109624A3 (en) | Monovalent and multivalent multispecific complexes and uses thereof | |
| WO2015112886A3 (en) | Binding proteins and methods of use thereof | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| WO2016179518A3 (en) | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof | |
| EP4218810A3 (en) | Multivalent meditopes, meditope-binding antibodies and uses thereof | |
| WO2015164392A8 (en) | Novel anti-rnf43 antibodies and methods of use | |
| EP3554544A4 (en) | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE | |
| EP3824096A4 (en) | NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF | |
| MX2018016096A (es) | Anticuerpos antagonistas de anti-axl. | |
| EP3424498A4 (en) | NANO CAPSULE WITH MONOCLONAL ANTIBODY FOR TUMOR THERAPY AND MANUFACTURING METHOD AND USE THEREOF | |
| MX2020002241A (es) | Anticuerpos anti-tm4sf y métodos de uso de los mismos. | |
| EP3790903A4 (en) | FULLY HUMAN ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THEREOF, AND USE THEREOF | |
| EP3418305A4 (en) | METHODS OF EXPRESSION AND PREPARATION OF BIVALENT BISPECIFIC ANTIBODY HYBRID PROTEIN | |
| WO2018069871A3 (en) | Anti-kras binding proteins | |
| WO2018111670A3 (en) | Antibodies to human alpha-synuclein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14891663 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14891663 Country of ref document: EP Kind code of ref document: A1 |